Blind Challenges
Predicting PXR Induction - We have liftoff
Launch details for the PXR induction challenge, including the dataset, rules, and practical guidance for participants.
Blind Challenges
Blind Challenges
Lessons Learned from the OpenADMET-ExpansionRx Blind Challenge: Can We Trust Zero-Shot ADMET Predictions?
Lessons and reflections from the OpenADMET-ExpansionRx blind challenge — evaluating whether zero-shot ADMET predictions can be trusted in real drug discovery settings.
Blind Challenges
Announcing the next OpenADMET Blind Challenge: Predicting PXR Induction
An introduction to the next blind challenge and why blinded datasets remain important for realistic benchmarking.
Blind Challenges
Lessons Learned from the OpenADMET - ExpansionRx Blind Challenge
Maria Castellanos Hugo MacDermott-Opeskin Jon Ainsley Pat Walters The ExpansionRx challenge, launched on October 27, 2025, closed two weeks ago! We are extremely grateful to everyone who participated and made this incredible learning experience possible for the ML and ADMET communities. After releasing the final leaderboard in our previous blogpost.
Blind Challenges
The OpenADMET - ExpansionRx Blind Challenge has Come to an End
Maria Castellanos Hugo MacDermott-Opeskin Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties can make or break the preclinical and clinical development of small molecules. At OpenADMET we aim to address the unpredictable nature of these properties through open science, generating high-quality experimental data and building robust predictive models of ADMET
Blind Challenges
OpenADMET - ExpansionRx Blind Challenge
Intermediate leaderboard release Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties can make or break the preclinical and clinical development of small molecules. At OpenADMET we address the unpredictable nature of these properties through open science, generating experimental data and building predictive models of ADMET properties. A key component of
Blind Challenges
Announcement 2: ExpansionRx - OpenADMET Blind Challenge
Additional details on the coming challenge Absorption, Distribution, Metabolism, Excretion and Toxicity–ADMET–properties can make or break preclinical and clinical development of small molecules. At OpenADMET we address the unpredictable nature of these properties through open science, generating experimental data and building predictive models of ADMET properties. A key
Blind Challenges
Announcement 1: ExpansionRx-OpenADMET Blind Challenge
Small molecules continue to be the bricks and mortar of drug discovery globally, accounting for ~75% of FDA approvals over the last decade. Oral bioavailability, easily tunable properties, modulation of a wide range of mechanisms, and ease of manufacturing make small molecules highly attractive as therapeutic agents. Moreover, emerging small